II2 Stock Chart & Stats
€0.66
€0.00(0.00%)
At close: 4:00 PM EDT
€0.66
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.45 - €2.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€23.99M
Enterprise Value€31.87M
Total Cash (Recent Filing)€30.42M
Total Debt (Recent Filing)€1.97M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 10, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding46,489,117
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.97Price Target Upside349.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.52
Revenue Forecast (FY)€8.96M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits interest and refinancing pressure relative to the company’s equity base. That gives InspireMD more flexibility to pursue regulatory and commercial milestones, although continuing losses could still weaken its capital position over time.
International Revenue GrowthInternational growth demonstrates continued physician adoption and demand for CGuard outside the United States despite the domestic commercial pause. A broader geographic revenue base can support future scale and reduce reliance on a single market once U.S. sales resume.
Regulatory And Product PipelineMultiple regulatory and product milestones provide a pathway to expand CGuard across carotid stenting and TCAR markets. If approvals and testing progress as planned, the pipeline could enlarge the addressable market and create a foundation for renewed commercial growth.
Bears Say
Severe Cash BurnDeeply negative operating and free cash flow show that the business is not self-funding and continues consuming cash to operate. This raises the importance of successful approvals, relaunch revenue, cost savings, or additional financing for maintaining execution capacity.
Large Operating LossesLosses remain extremely large compared with the company’s modest revenue base, indicating that the current cost structure is far from breakeven. Sustained negative margins can absorb capital, limit investment flexibility, and make profitability dependent on substantial commercial scale.
Recall And Regulatory Execution RiskThe recall has disrupted U.S. commercialization and directly damaged reported gross profit through credits and inventory impairment. Relaunch timing also depends on remaining testing and FDA review, creating execution uncertainty before the affected product can contribute meaningfully.
InspireMD News
II2 FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was €0.45 and its highest was €2.06 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is €23.99M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Nov 10, 2026 which is in 33 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on Aug 17, 2026. The company reported -€0.151 earnings per share for the quarter, beating the consensus estimate of -€0.178 by €0.027.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.14.
How many shares outstanding does InspireMD have?
InspireMD has 46,489,117 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -€0.151 in its last earnings report, beating expectations of -€0.178. Following the earnings report the stock price went up 6.107%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in DE:II2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InspireMD
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
II2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of encouraging operational and regulatory progress (21% international revenue growth, constructive FDA interactions, multiple potential approvals, enrollment in a pivotal SwitchGuard study, and planned annualized cost savings of ~$9 million) alongside significant near‑term challenges (voluntary recall driving $734k in customer credits and a $612k inventory impairment, a swing to negative GAAP gross margin, a wider net loss of $14.3M, and a substantial cash decline from $54.2M to $30.4M). Management articulated a clear remediation and relaunch plan and emphasized underlying demand, but financial impacts and regulatory timing risk keep the outlook balanced between opportunity and near‑term execution/liquidity challenges.View all DE:II2 earnings summariesII2 Stock 12 Month Forecast
Average Price Target
€2.97
▲(349.36% Upside)